Clinical Trials Logo

Pain Uterus clinical trials

View clinical trials related to Pain Uterus.

Filter by:
  • None
  • Page 1

NCT ID: NCT03636451 Completed - Clinical trials for Abortion in First Trimester

Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o

Start date: October 29, 2018
Phase: Phase 3
Study type: Interventional

The investigators are conducting a study on pain control for dilation and curettage (D&C). Participants are eligible to enroll if they are a planning to have a D&C in a participating clinic. The investigators are studying how different ratios of medication to liquid affect pain when injected around the cervix. Both potential methods use the same dose of medication, though researchers would like to know which one works better. To be in this study, participants must be over the age of 18 with an early pregnancy loss or undesired pregnancy measuring less than 12 weeks gestation undergoing D&C while awake in clinic.

NCT ID: NCT03382743 Recruiting - Pain Uterus Clinical Trials

Endocervical Lidocaine Spray for Pain Control During Office Hysteroscopy

Start date: December 20, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

lidocaine spray is used endocervical before office hysteroscopy to reduce the pain

NCT ID: NCT03314792 Completed - Pain, Postoperative Clinical Trials

Effects of Tapentadol Versus Oxycodone After Hysterectomy.

Start date: December 4, 2017
Phase: Phase 4
Study type: Interventional

Opioids remain the first-line drugs for the treatment of moderate to severe postoperative pain, but the use is limited by well-known side-effects, most of which are dose-dependent. The opioid oxycodone is standard therapeutic treatment for acute postoperative pain, either in immediate-release formulation, OxyNorm®, or as extended-release formulation, OxyContin®. Oxycodone provides analgesic effects through µ-opioid receptors in the central nervous system. Tapentadol hydrochloride/depot (Palexia/depot®) is a novel, centrally acting, strong analgesic with a dual mechanism of action on µ-opioid receptors and noradrenaline reuptake in the central nervous system. Tapentadol is an active compound, devoid of active metabolites and not reliant on enzyme systems. For these reasons, it has a low drug interaction potential. This dual mechanism also translates clinically into less adverse effects than with pure opioid agonists like oxycodone. This is probably due to less µ-opioid receptor stimulation. Tapentadol has been shown effective in models of acute, osteoarthritic, neuropathic and cancer pain. There is now an increasing use of tapentadol in postoperative pain treatment in Norway. However, there is a lack of broad-based evidence for the use of tapentadol in the post-surgical setting. So far, to our knowledge, there are only published studies on postoperative pain treatment after orthopedic and dental surgery, but none related to deep abdominal pain. Tapentadol is shown in several studies on chronic pain patients to have comparable analgesic effects to traditional opioid pain medications like oxycodone and morphine, but with a more tolerable side-effect profile. In the postoperative setting after dental or orthopedic surgery, studies have shown less nausea and constipation. It has also been suggested a lower frequency of pruritus compared with oxycodone, but no difference in central nervous system symptoms such as sleepiness or dizziness. The most dangerous side-effect from opioids is respiratory depression with the potential of fatal outcome. The investigators have not found any publications from short-term postoperative pain management comparing the respiratory effect of tapentadol to the traditional opioids. The aim of the study is to compare the analgesic effect and side-effects of this new analgesic, tapentadol, to the standard treatment to day, oxycodone, in the acute postoperative period after hysterectomy.

NCT ID: NCT03279666 Completed - Pain Uterus Clinical Trials

Biopsy Size and Pain Perception During Colposcopic Biopsy

Start date: June 15, 2017
Phase: N/A
Study type: Interventional

The investigators will investigate patients pain and biopsy size during colposcopic biopsy. The investigators will use tenaculum randomized patient with or without intracervical blockage.

NCT ID: NCT03057041 Completed - Pain Uterus Clinical Trials

Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration

Start date: March 23, 2017
Phase: N/A
Study type: Interventional

Intranasal fentanyl has been found to be safe and effective in the reduction of pain among pediatric and adult populations. The investigators hypothesize that patients who receive 100 mcg of intranasal fentanyl for pain control before first-trimester uterine aspiration will report lower pain scores than those who receive placebo. The investigators will test this hypothesis using a randomized, double-blind, placebo-controlled trial comparing pain reported during uterine aspiration between patients who receive either intranasal fentanyl or intranasal saline prior to the procedure.